ArticleBlood cancer discovery2021

A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid Neoplasms.

Yihong Guan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.